Annual EBITDA
-$70.54 M
+$4.15 M+5.56%
December 31, 2023
Summary
- As of February 7, 2025, ACHL annual EBITDA is -$70.54 million, with the most recent change of +$4.15 million (+5.56%) on December 31, 2023.
- During the last 3 years, ACHL annual EBITDA has fallen by -$37.59 million (-114.06%).
- ACHL annual EBITDA is now -423.58% below its all-time high of -$13.47 million, reached on December 31, 2019.
Performance
ACHL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$20.42 M
-$2.62 M-14.71%
September 1, 2024
Summary
- As of February 7, 2025, ACHL quarterly EBITDA is -$20.42 million, with the most recent change of -$2.62 million (-14.71%) on September 1, 2024.
- Over the past year, ACHL quarterly EBITDA has dropped by -$2.05 million (-11.17%).
- ACHL quarterly EBITDA is now -273.32% below its all-time high of -$5.47 million, reached on March 31, 2020.
Performance
ACHL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$69.70 M
-$1.32 M-1.93%
September 1, 2024
Summary
- As of February 7, 2025, ACHL TTM EBITDA is -$69.70 million, with the most recent change of -$1.32 million (-1.93%) on September 1, 2024.
- Over the past year, ACHL TTM EBITDA has increased by +$3.30 million (+4.52%).
- ACHL TTM EBITDA is now -1174.47% below its all-time high of -$5.47 million, reached on March 31, 2020.
Performance
ACHL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ACHL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.6% | -11.2% | +4.5% |
| 3 y3 years | -114.1% | -34.8% | +0.9% |
| 5 y5 years | -423.6% | -34.8% | +0.9% |
ACHL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -15.8% | +5.6% | -55.6% | +7.2% | -14.4% | +9.1% |
| 5 y | 5-year | -423.6% | +5.6% | -273.3% | +7.2% | -1174.5% | +9.1% |
| alltime | all time | -423.6% | +5.6% | -273.3% | +7.2% | -1174.5% | +9.1% |
Achilles Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$20.42 M(+14.7%) | -$69.70 M(+1.9%) |
| Jun 2024 | - | -$17.80 M(+35.7%) | -$68.38 M(-0.4%) |
| Mar 2024 | - | -$13.12 M(-28.6%) | -$68.67 M(-5.9%) |
| Dec 2023 | -$70.54 M(-5.6%) | -$18.37 M(-3.8%) | -$73.00 M(-4.7%) |
| Sep 2023 | - | -$19.10 M(+5.5%) | -$76.64 M(+5.4%) |
| Jun 2023 | - | -$18.09 M(+3.7%) | -$72.68 M(-2.1%) |
| Mar 2023 | - | -$17.45 M(-20.7%) | -$74.22 M(-0.6%) |
| Dec 2022 | -$74.69 M | -$22.00 M(+45.3%) | -$74.69 M(+6.2%) |
| Sep 2022 | - | -$15.14 M(-22.9%) | -$70.31 M(+0.3%) |
| Jun 2022 | - | -$19.63 M(+9.6%) | -$70.08 M(+6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$17.92 M(+1.7%) | -$65.90 M(+8.2%) |
| Dec 2021 | -$60.91 M(+84.8%) | -$17.62 M(+18.2%) | -$60.91 M(+9.1%) |
| Sep 2021 | - | -$14.91 M(-3.6%) | -$55.80 M(+13.4%) |
| Jun 2021 | - | -$15.46 M(+19.7%) | -$49.20 M(+20.9%) |
| Mar 2021 | - | -$12.92 M(+3.2%) | -$40.68 M(+22.4%) |
| Dec 2020 | -$32.95 M(+144.6%) | -$12.52 M(+50.8%) | -$33.23 M(+60.5%) |
| Sep 2020 | - | -$8.30 M(+19.6%) | -$20.71 M(+66.9%) |
| Jun 2020 | - | -$6.94 M(+26.9%) | -$12.41 M(+126.9%) |
| Mar 2020 | - | -$5.47 M | -$5.47 M |
| Dec 2019 | -$13.47 M | - | - |
FAQ
- What is Achilles Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Achilles Therapeutics?
- What is Achilles Therapeutics annual EBITDA year-on-year change?
- What is Achilles Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Achilles Therapeutics?
- What is Achilles Therapeutics quarterly EBITDA year-on-year change?
- What is Achilles Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Achilles Therapeutics?
- What is Achilles Therapeutics TTM EBITDA year-on-year change?
What is Achilles Therapeutics annual EBITDA?
The current annual EBITDA of ACHL is -$70.54 M
What is the all time high annual EBITDA for Achilles Therapeutics?
Achilles Therapeutics all-time high annual EBITDA is -$13.47 M
What is Achilles Therapeutics annual EBITDA year-on-year change?
Over the past year, ACHL annual EBITDA has changed by +$4.15 M (+5.56%)
What is Achilles Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ACHL is -$20.42 M
What is the all time high quarterly EBITDA for Achilles Therapeutics?
Achilles Therapeutics all-time high quarterly EBITDA is -$5.47 M
What is Achilles Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ACHL quarterly EBITDA has changed by -$2.05 M (-11.17%)
What is Achilles Therapeutics TTM EBITDA?
The current TTM EBITDA of ACHL is -$69.70 M
What is the all time high TTM EBITDA for Achilles Therapeutics?
Achilles Therapeutics all-time high TTM EBITDA is -$5.47 M
What is Achilles Therapeutics TTM EBITDA year-on-year change?
Over the past year, ACHL TTM EBITDA has changed by +$3.30 M (+4.52%)